How is Diamond-Blackfan anemia 2 diagnosed?

Information about diagnosis is currently limited for this condition.

Are there treatments for Diamond-Blackfan anemia 2?

Information about treatment is currently limited for this condition.

What complications can arise from Diamond-Blackfan anemia 2?

Information about complications from Diamond-Blackfan anemia 2 is currently limited. However, patients with this condition may face challenges related to their anemia, such as fatigue and increased risk of infections. It's important to monitor health closely and discuss any concerns with a healthcare provider.

How does Diamond-Blackfan anemia 2 affect daily life?

Daily life for someone with Diamond-Blackfan anemia 2 may involve managing symptoms like fatigue and weakness. Patients might need to adjust their activities based on how they feel. It's essential to have a good support system and communicate with family and friends about any limitations.

What is the prognosis for someone with Diamond-Blackfan anemia 2?

Currently, there is limited information about the prognosis for Diamond-Blackfan anemia 2. Prognosis can vary based on individual circumstances and how well the condition is managed. Regular check-ups with healthcare providers can help in monitoring health and making necessary adjustments.

Are there any special considerations for family planning with Diamond-Blackfan anemia 2?

There is limited information regarding family planning specifically for individuals with Diamond-Blackfan anemia 2. It may be helpful to discuss any concerns with a healthcare provider, especially regarding genetic factors and the potential for passing on the condition. Open communication with partners about health is also important.

Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

Diamond-Blackfan anemia 2 (DBA2) - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

Diamond-Blackfan anemia 2

MONDO:0011636

Also known as:DBA2Diamond-Blackfan Anemia, 2anaemia Diamond-Blackfan 2

Overview

Clinical Presentation

Built from Human Phenotype Ontology (HPO) phenotype annotations and GeneReviews clinical descriptions. Features represent findings documented across known cases — not an exhaustive list of possible symptoms.

No HPO annotations are available for this condition.

GeneReviews

Clinical Guidance

DBA syndrome is characterized by early-onset hypoplastic anemia. Congenital anomalies are observed in approximately 50% of affected individuals and more than one anomaly is observed in up to 25% of individuals. Additional features include growth deficiency and predisposition to malignancy. Table 2. DBA Syndrome: Frequency of Select Features

Diagnosis

Drawn from GeneReviews diagnostic guidelines, newborn screening panel status (RUSP), and ClinGen gene-disease validity classifications. Reflects current clinical evidence and consensus where available.

GeneReviews

Diagnostic Criteria

Suggestive Findings

DBA syndrome should be suspected in individuals with the following clinical, laboratory, and histopathologic features, and no evidence of another inherited disorder of bone marrow function.

Clinical features

Pallor, weakness, poor weight gain
Growth deficiency (observed in 30%)

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

No approved treatments are currently available for Diamond-Blackfan anemia 2. The disease remains an area of unmet medical need.

GeneReviews

Management Guidelines

Clinical practice guidelines for treatment and surveillance of individuals with DBA syndrome have been published . Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with DBA syndrome, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended. Table 4. DBA Syndrome: Recommended Evaluations Following Initial Diagnosis

Prognosis

Based on GeneReviews surveillance recommendations, HPO phenotype frequency and severity annotations, and published prevalence estimates from Orphanet and OMIM.

GeneReviews

Surveillance Guidelines

To monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, the evaluations summarized in are recommended.

Table 7.

DBA Syndrome: Recommended Surveillance

System/Concern | Evaluation | Frequency

Hematologic

| Complete blood count | 1-2x/yr in responsive persons when hemoglobin is stable

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

No clinical trials have been registered for Diamond-Blackfan anemia 2.

36 publications have been identified in PubMed for Diamond-Blackfan anemia 2. Research spans Case Report / Case Series (31%), Basic Science / Preclinical (31%), and Review / Meta-Analysis (8%).

Research Type	Count	% of Total
Patient case studies	11	31%

Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 1:57 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

OMIM

Online Mendelian Inheritance in Man

OMIM:606129

GARD

Genetic and Rare Diseases Info Center

GARD:8283

Questions for Your Care Team

→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

FAQ

Frequently Asked Questions

Common questions about Diamond-Blackfan anemia 2

Information about overview is currently limited for this condition.

Information about symptoms is currently limited for this condition.

Current information indicates that Diamond-Blackfan anemia 2 is associated with the DBA2 gene. Further details about the genetic changes and risk factors are not available in the provided sources.

← Back to All Diseases

Feature	% of Personsw/Feature1	Comment
Anemia	99%	90% in 1st year of life; Rarely, DBA syndrome is diagnosed w/o anemia.
Craniofacial features	27%	—
Upper-limb anomalies	16%	—
Genitourinary malformations	13%	—
Heart defects	11%	—
Growth deficiency	30%	—
Malignancy	2%-5%	Acute myelogenous leukemia, myelodysplastic syndrome, solid tumors incl osteogenic sarcoma lung, colon, cervical carcinomas 1. Anemia. The primary hematologic feature of DBA syndrome is a profound normochromic, macrocytic anemia with normal leukocytes and platelets.

System/Concern	Evaluation	Comment
anomalies	Eval by clinical pediatric hematologist geneticist for congenital malformations incl cleft lip/palate	Skeletal anomalies
Cardiology	Eval by cardiologist incl echocardiography	—
Endocrine	Growth assessment	—
Development	Developmental assessment	Genetic
counseling	By genetics professionals1	To obtain a pedigree inform affected persons their families re nature, MOI, implications of DBA syndrome to facilitate medical personal decision making Family support
resources	By clinicians, wider care team, family support organizations	Assessment of family social structure to determine need for:; Community or such as Parent to Parent; Social work involvement for parental support; Home nursing referral The Diamond Blackfan Anemia Foundation lists resources for family support.
DBA Syndrome: Targeted Therapies Type	Treatment	Dosage
Corticosteroids	Prednisone	Starting dose: 2 mg/kg/day orally 1x daily in am for 4 weeks. If no response, taper over 2 weeks.; Slowly taper responders to minimal effective dose (0.3 mg/kg/day is target daily dose or preferably 0.6 mg/kg every other day to avoid adrenal suppression).1
Can improve RBC count in 60%-80% of persons Transplant	HSCT	See the following text.

Kisho

Diamond-Blackfan anemia 2

Overview

Clinical Presentation

Clinical Guidance

Diagnosis

Diagnostic Criteria

Suggestive Findings

Treatment

Management Guidelines

Prognosis

Surveillance Guidelines

Hematologic

Research Landscape

Medical References

External Resources

OMIM

GARD

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

Differential Diagnosis

Clinical Guidance

Therapies Under Investigation

Clinical Trials

Complications of corticosteroid therapy

Transfusion-related iron overload

Recent Publications

Diamond-Blackfan anemia 2

Overview

Clinical Presentation

Clinical Guidance

Diagnosis

Diagnostic Criteria

Suggestive Findings

Treatment

Management Guidelines

Prognosis

Surveillance Guidelines

Hematologic

Research Landscape

Medical References

External Resources

OMIM

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

What is Diamond-Blackfan anemia 2?

What are the symptoms of Diamond-Blackfan anemia 2?

What causes Diamond-Blackfan anemia 2?

How is Diamond-Blackfan anemia 2 diagnosed?

Are there treatments for Diamond-Blackfan anemia 2?

What complications can arise from Diamond-Blackfan anemia 2?

How does Diamond-Blackfan anemia 2 affect daily life?

What is the prognosis for someone with Diamond-Blackfan anemia 2?

Are there any special considerations for family planning with Diamond-Blackfan anemia 2?

Differential Diagnosis

Clinical Guidance

Therapies Under Investigation

Clinical Trials

Complications of corticosteroid therapy

Transfusion-related iron overload

Recent Publications